drugset / Trial / NCT05686746
Use of Baricitenib to Maintain of Remission
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Baricitinib a selective Janus kinase (JAK) inhibitors 1\&2 have been recognized as a potential therapeutic option in systemic lupus (SLE), also known Baricitinib, a JAK inhibitor, has demonstrated efficacy and safety in the treatment of dermatitis and arthritis 1 ; however, no JAK inhibitor studies have been conducted in lupus nephritis (LN) maintain remission to date.
Timeline
- Start
- 2022-06-01
- Primary completion
- 2023-06-01
- Completion
- 2023-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | 2 mg | Oral |
| Subject | Baricitinib | Small molecule | 4 mg | Oral |
| Comparator | MMF | Unknown | 1000 mg | Oral |